|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.200 AUD | +1.27% |
|
-2.44% | -50.00% |
| Jul. 10 | ASX Biggest Losers | MT |
| Jul. 03 | OncoSil Medical Completes Patient Recruitment for Pancreatic Cancer Study | MT |
Company Valuation: OncoSil Medical Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 33.43 | 95.29 | 42.26 | 39.65 | 23.71 | 13.33 |
| Change | - | 185.06% | -55.65% | -6.18% | -40.2% | -43.79% |
| Enterprise Value (EV) 1 | 25.74 | 74.4 | 30.5 | 28.67 | 14.49 | 8.898 |
| Change | - | 189.07% | -59% | -6% | -49.47% | -38.58% |
| P/E ratio | -3.89x | -17.7x | -4.14x | -3.02x | -1.2x | -0.74x |
| PBR | 3.13x | 4.35x | 3.61x | 3.55x | 2.4x | 2.81x |
| PEG | - | 0.3x | -0x | -0.9x | 0x | 0x |
| Capitalization / Revenue | 9.22x | 34.5x | 32.5x | 37.3x | 16.2x | 8.51x |
| EV / Revenue | 7.1x | 26.9x | 23.5x | 27x | 9.87x | 5.68x |
| EV / EBITDA | -2.94x | -16.8x | -2.9x | -2.72x | -1.28x | -0.74x |
| EV / EBIT | -2.93x | -16.7x | -2.89x | -2.71x | -1.28x | -0.74x |
| EV / FCF | -5.86x | -24.8x | -5.93x | -4.55x | -2.03x | -1.36x |
| FCF Yield | -17.1% | -4.03% | -16.9% | -22% | -49.3% | -73.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -5.452 | -2.6 | -5.12 | -5.292 | -4.017 | -2.16 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3.626 | 2.764 | 1.298 | 1.063 | 1.467 | 1.565 |
| EBITDA 1 | -8.747 | -4.419 | -10.51 | -10.55 | -11.32 | -11.98 |
| EBIT 1 | -8.786 | -4.446 | -10.54 | -10.58 | -11.34 | -11.98 |
| Net income 1 | -8.567 | -4.262 | -10.43 | -10.73 | -11.34 | -11.91 |
| Net Debt 1 | -7.689 | -20.89 | -11.76 | -10.98 | -9.223 | -4.431 |
| Reference price 2 | 21.200 | 45.999 | 21.200 | 15.999 | 4.800 | 1.600 |
| Nbr of stocks (in thousands) | 1,577 | 2,072 | 1,993 | 2,478 | 4,940 | 8,330 |
| Announcement Date | 8/22/19 | 8/19/20 | 8/18/21 | 8/30/22 | 8/31/23 | 9/30/24 |
1AUD in Million2AUD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 11.03M | ||
| 37.15x | 12.26x | 27.92x | 0.75% | 709B | ||
| 14.75x | 4.45x | 12.66x | 3.18% | 396B | ||
| 26.07x | 6.52x | 13.7x | 3.43% | 337B | ||
| 16.67x | 6.04x | 12.08x | 3.04% | 301B | ||
| 14.12x | 3.48x | 8.61x | 3.85% | 258B | ||
| 17.19x | 4.58x | 11.09x | 3.32% | 234B | ||
| 22.1x | 4.13x | 12.15x | 2.29% | 218B | ||
| 10.56x | 3.43x | 7.41x | 3.9% | 207B | ||
| 22.86x | 5.83x | 11.25x | 3.21% | 161B | ||
| Average | 20.16x | 5.64x | 12.99x | 3% | 282.05B | |
| Weighted average by Cap. | 22.80x | 6.73x | 15.55x | 2.64% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- OSL Stock
- Valuation OncoSil Medical Limited
Select your edition
All financial news and data tailored to specific country editions
